Evidence map›Paper›PMID 38192673›Full record

ArticleOncology letters2024

Successful treatment with trastuzumab plus chemotherapy as the first‑line regimen in advanced small bowel adenocarcinoma harboring HER2 amplification: A report of two cases.

Jingwen Wang, Xia Zhu, Jiayan Chen, Fei Liu, Xi Tang

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Progress in the treatment of duodenal cancer: A comprehensive review.World journal of gastrointestinal oncology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jingwen WangDepartment of Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Xia ZhuDepartment of Pathology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Jiayan ChenDepartment of Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Fei LiuDepartment of Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Xi TangDepartment of Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, P.R. China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic options are limited for individuals with unresectable or metastatic small bowel adenocarcinoma (SBA), necessitating palliative chemotherapy. Human epidermal growth factor receptor 2 (HER2) gene amplification or protein overexpression in SBA is exceedingly rare. HER2 amplification mutations/overexpression serves as a potential target for treatment in various malignancies. However, research on targeted therapies for SBA with

Indexed as

amplificationchemotherapyhuman epidermal growth factor receptor 2small bowel adenocarcinomatargeted therapy

Identifiers

PMID38192673
PMCPMC10773192
OpenAlexW4389893207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.